Klothos Neurosciences Inc.

Company Overview

Business Model: Greenland Mines Ltd (formerly Klotho Neurosciences, Inc.) is a development-stage company focused on essential medicines for chronic diseases, including cancer, cardiovascular, and neurodegenerative disorders. The Company operates through two primary licensed platforms: a generic drug portfolio and a biosimilar biologics platform for cancer treatment, and a proprietary, patented gene therapy platform utilizing the "Klotho" protein for neurodegenerative diseases. Subsequent to the fiscal year ended December 31, 2025, in March 2026, the Company expanded its operations into the development and mining of critical and precious minerals through the acquisition of Greenland Mines Corp.

Market Position: The Company's gene therapy platform is based on proprietary, patented technology for the α-Klotho sequence s-KL, targeting neurodegenerative diseases such as Alzheimer's disease and Amyotrophic Lateral Sclerosis (ALS). The Company claims no direct competition in ALS, AD, PD, or other neurodegenerative disorders involving the human s-KL Klotho gene or s-KL protein. In the biosimilar market, the Company holds licenses for off-patent versions of rituximab, trastuzumab, bevacizumab, and cetuximab. The generic drug portfolio includes five market-approved anti-cancer drugs for sale in Germany. The Company faces significant competition from major pharmaceutical companies, specialty pharmaceutical companies, and biotechnology companies in both the biosimilar and gene therapy markets.

Recent Strategic Developments:

• March 2026: Completed the acquisition of Greenland Mines Corp., diversifying into critical and precious minerals mining.
• March 11, 2026: Changed its corporate name to Greenland Mines Ltd.
• March 2, 2026: Closed a private placement, issuing 34,551,939 common shares and warrants, generating approximately $7,750,000 in gross proceeds.
• February 17, 2026: Stockholders approved a reverse stock split (exchange ratio between one-for-2 to one-for-50) and an increase in shares reserved for the 2024 Equity Incentive Plan to 10,000,000.
• July 3, 2025: Entered into an At-the-Market sales agreement with A.G.P./Alliance Global Partners to sell up to $50,000,000 of common stock.
• 2025: Initiated a warrant exercise inducement program, reducing the exercise price from $3.49 to $1.35 for certain outstanding warrants.
• June 13, 2025: Terminated a Share Exchange Agreement to acquire SB Security Holdings, LLC.
• 2025: Plans to complete animal toxicology for KLTO-202 (ALS gene therapy) and submit an Investigational New Drug (IND) application to the FDA for a Phase I "Compassionate Use" study.

Geographic Footprint: The Company's generic drug portfolio is approved for sale in Germany. Its biosimilar biologics platform has exclusive licensed rights for North America, Europe, and Israel. The gene therapy platform aims for market approval in the U.S., Canada, Europe, China, and other viable markets, supported by patents issued in the U.S., Europe, China, and Hong Kong, with applications pending in Canada, Japan, Korea, and India. The Company maintains offices in Charlotte, NC, and Omaha, NE. Following the March 2026 acquisition, the Company gained three additional employees based in Europe.

Financial Performance

Revenue Analysis

Profitability Metrics:

• Gross Margin: N/A (no revenue)
• Operating Margin: N/A (no revenue)
• Net Margin: N/A (no revenue)

Investment in Growth:

• R&D Expenditure: $634,187 (2025) vs. $0 (2024)
• Capital Expenditures: $0 (2025) vs. $123,497 (2024) (related to acquisition of drug license)
• Strategic Investments: The Company's primary investments are in acquiring and licensing intellectual property for its drug platforms. This includes the acquisition of five market-approved anti-cancer drugs, two off-patent bio generic antibodies from Reliance Life Sciences, and exclusive licenses for gene therapy technology from Universitat Autònoma de Barcelona and University of Heidelberg.

Business Segment Analysis

The Company operates as a single reporting segment, focusing on the research and development of essential medicines for the treatment of chronic diseases – cancer, cardiovascular, and neurodegenerative disorders. The Chief Operating Decision Maker (CEO) manages and allocates resources on a total company basis, using consolidated financial information to evaluate performance, forecast results, and allocate resources across functions and R&D projects.

Capital Allocation Strategy

Shareholder Returns:

• Share Repurchases: Not disclosed for the periods presented.
• Dividend Payments: The Company has not declared or paid dividends on its common shares since its formation and does not anticipate paying dividends in the foreseeable future, intending to retain any future earnings for business operations.
• Dividend Yield: N/A
• Future Capital Return Commitments: No specific future capital return commitments were disclosed.

Balance Sheet Position:

• Cash and Equivalents: $7,176,615 (2025) vs. $63,741 (2024)
• Total Debt: $0 (2025) vs. $271,753 (2024) (Notes payable to related parties and Notes payable)
• Net Cash Position: $7,046,851 (2025) vs. $(1,208,280) (2024) (Cash and Equivalents less Total Liabilities)
• Credit Rating: Not disclosed.
• Debt Maturity Profile: All notes payable to related parties and other notes payable were fully settled as of December 31, 2025.

Cash Flow Generation:

• Operating Cash Flow: $(5,889,254) (2025) vs. $(2,946,512) (2024)
• Free Cash Flow: Not explicitly calculated, but negative due to operating cash outflows and minimal investing activities.
• Cash Conversion Metrics: Not disclosed.

Operational Excellence

Production & Service Model: The Company's operational philosophy centers on the development of essential medicines. This involves a gene therapy approach to introduce therapeutic proteins, a biosimilar biologics platform, and a generic drug portfolio. The gene therapy product candidates are in the pre-clinical stage, with plans for an IND submission for KLTO-202 in 2025. The Company relies on Contract Research Organizations (CROs) and Contract Development and Manufacturing Organizations (CDMOs) for manufacturing, quality control testing, and the conduct of preclinical and clinical trials.

Supply Chain Architecture: Key Suppliers & Partners:

• API Supply (Biosimilars): Reliance Life Sciences (exclusive provider of Active Pharmaceutical Ingredients for biosimilars).
• Gene Therapy Technology: Universitat Autònoma de Barcelona (exclusive, worldwide license for α-Klotho sequence s-KL and related know-how). University of Heidelberg (non-exclusive, worldwide license for modified AAV capsid polypeptides).
• Research Collaboration: Universitat Autònoma de Barcelona (Sponsored Research Agreement with Dr. Assumpcio Bosch and Dr. Miguel Chillon's laboratory, with a two-year budget of 623,100 euros).
• Manufacturing & Clinical Trials: Relies on third-party CROs and CDMOs for these functions.

Facility Network:

• Offices: The Company utilizes two offices, each approximately 400 sq ft, located in Omaha, NE (provided rent-free by the CEO) and Charlotte, NC (rented for $700 per month).
• Manufacturing: The Company does not own manufacturing facilities, relying on third-party CDMOs whose facilities are subject to FDA inspections for cGMP compliance.
• Research & Development: R&D activities are conducted internally and through collaborations, notably with Universitat Autònoma de Barcelona.

Operational Metrics: Specific operational metrics such as capacity utilization or efficiency measures were not disclosed in the filing.

Market Access & Customer Relationships

Go-to-Market Strategy: Distribution Channels: The Company currently has no products approved for commercial sale. Upon potential regulatory approval, it intends to establish its own sales and marketing organization with technical expertise and distribution capabilities in major markets where it retains commercialization rights. For ex-U.S. markets, the Company may seek agreements or joint ventures with other pharmaceutical companies.

Customer Portfolio: Not applicable, as the Company has not generated any revenue from product sales.

Geographic Revenue Distribution: Not applicable, as the Company has not generated any revenue.

Competitive Intelligence

Market Structure & Dynamics

Industry Characteristics: The Company operates in highly competitive pharmaceutical markets characterized by rapid technological change. The gene therapy sector is novel, with a limited number of approved products. The biosimilar market is marked by intense price competition, particularly in Europe where biosimilar entry has led to significant price reductions (30%-40% or more) for innovator products. The U.S. biosimilar market is also experiencing decreasing prices. The Company's focus on neurodegenerative disorders addresses a rapidly aging global population, with Alzheimer's disease being the most common type of senile dementia and ALS a devastating motor system disorder.

Competitive Positioning Matrix:

Direct Competitors

Primary Competitors:

• Gene Therapy (Alzheimer's): University of California San Diego School of Medicine (Phase I clinical trial for brain-derived neurotrophic factor (BDNF) gene therapy).
• Gene Therapy (Klotho-related): Unity Biotechnology (preclinical Klotho product candidate, no data reported); Jocasta Therapeutics, Inc. (licensed Dubal Klotho technology, expects IND in 2026, pursuing full-length protein therapy).
• Gene Therapy (ALS): Biogen (anti-sense oligonucleotides for ataxin-2), Eikonoklastes Therapeutics (Caveolin-1), Neurosense Therapeutics (ciprofloxacin and celecoxib combination). Amylyx (Relyvrio, removed from market).
• Gene Therapy (Parkinson's Disease): AXO-Lenti-PD (investigational gene therapy for dopamine synthesis).
• Biosimilars (Rituximab): Pfizer Inc., Mylan Inc., Amgen Inc., Teva Pharmaceutical Industries LTD, Celltrion Healthcare Co. LTD, Sandoz International GmbH, Reliance Life Sciences, C.H. Boehringer Sohn AG & Co. KG, BioXpress Therapeutics SA, Intas Biopharmaceuticals LTD.
• Biosimilars (Bevacizumab): Amgen and Allergan (Mvasi), Pfizer (Zirabev).
• Generic/Branded Drugs (Cognitive Disorders/Dementia): Allergan, Eisai Co., LTD, Novartis AG, Daiichi Sankyo Company, Limited., Merz Pharma, Pfizer Inc., Johnson & Johnson Services, Inc., H. Lundbeck A/S, Biogen, AstraZeneca, F. Hoffmann-La Roche Ltd, VTV Therapeutics, TauRx, Eli Lilly and Company, Teva Pharmaceutical Industries LTD, Ono Pharmaceutical Co., LTD, AC Immune, AB Science, AbbVie Inc., Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited., Bayer AG.
• Anti-amyloid antibodies (Alzheimer's): Roche, Bristol-Myers/Celgene, Biogen (Aduhelm, removed from market), Lilly (Leqembi).

Emerging Competitive Threats: New entrants and disruptive technologies, including mRNA therapies (e.g., Klothea BIO, which is developing mRNA solutions to enhance Klotho secretion).

Competitive Response Strategy: The Company's strategy involves advancing its sustainable portfolio of cell and gene therapy product candidates, particularly for age-associated neurologic diseases. It is building a platform of next-generation gene and cell delivery technologies (AAV-based, Lentivirus-based, and lipid-based) and developing novel assays for Klotho protein isoforms. The Company also actively explores opportunities to acquire or license new product candidates and form strategic partnerships.

Risk Assessment Framework

Strategic & Market Risks

Market Dynamics:

• Product Development Risk: High dependence on the successful development, regulatory approval, and commercialization of early-stage biosimilar and pre-clinical gene therapy product candidates, with no current approved products.
• Competition: Intense competition from larger, more resourced pharmaceutical companies, potentially leading to more advanced, effective, or less expensive therapies, or earlier market entry.
• Market Acceptance: Risk that approved products may not achieve sufficient market acceptance due to novelty, physician comfort, cost, or side effects.
• Biosimilar Interchangeability: Risk that the Company's biosimilars may not be deemed "interchangeable" by regulatory authorities, impacting market penetration.
• Reference Product Obsolescence: Risk that improved versions of reference products or market declines for reference products could reduce potential sales of biosimilars.
• Negative Public Opinion: Gene therapy's novelty and past adverse events could lead to negative public perception, increased regulatory scrutiny, and delays in development or approval.

Operational & Execution Risks

Supply Chain Vulnerabilities:

• Third-Party Manufacturing Dependence: Reliance on contract development and manufacturing organizations (CDMOs) and Reliance Life Sciences for API supply. Risks include failure to meet regulatory requirements or supply demands.
• Clinical Trial Dependence: Reliance on contract research organizations (CROs) and clinical sites for trial conduct. Risks include delays in patient enrollment/retention, non-compliance with regulations, or unreliable data.
• New Technology Development Challenges: Gene therapy is a new technology, making development time and cost unpredictable. Challenges in developing sustainable, reproducible, and scalable manufacturing processes.
• Assay Development: Requirement to develop and validate new in vitro assays for Klotho isoforms; delays could impede gene therapy development.

Financial & Regulatory Risks

Market & Financial Risks:

• Funding Requirements: Substantial additional funding is required to complete development and commercialization, as current cash is insufficient.
• Significant Payment Obligations: Contractual milestone and royalty payments to licensors (Universitat Autònoma de Barcelona, Reliance Life Sciences) are significant and may be due before product sales.
• Reimbursement Uncertainty: Significant uncertainty regarding coverage and adequate reimbursement from third-party payors for future approved products.
• Price Competition: Biosimilar products will face intense price competition, potentially limiting profitability and market share.
• Nasdaq Delisting Risk: The Company received a delinquency notification for failing to maintain a minimum bid price of $1 per share and has been granted an extension until September 14, 2026, to regain compliance.
• Dilution: Future equity or debt financing could result in significant dilution for existing stockholders.
• Acquisition Risks: Future acquisitions or investments may not achieve intended results, adversely affect financial condition, or introduce unforeseen risks.

Regulatory & Compliance Risks:

• Evolving Regulatory Landscape: The regulatory approval processes by the FDA, EMA, and other foreign authorities are lengthy, rigorous, and unpredictable, with requirements subject to change.
• Undesirable Side Effects: Product candidates may cause undesirable side effects, potentially delaying or preventing regulatory approval, limiting commercial labeling, or leading to significant negative consequences post-marketing.
• Post-Approval Scrutiny: Approved products will be subject to ongoing and extensive regulatory requirements, including cGMP, labeling, reporting, and inspections.
• Healthcare Fraud and Abuse Laws: Operations are subject to federal and state healthcare fraud and abuse laws (e.g., Anti-Kickback Statute, False Claims Act, Physician Payments Sunshine Act, HIPAA), with non-compliance potentially leading to substantial penalties.
• Environmental, Health and Safety: Research, development, and manufacturing activities involve hazardous materials, subjecting the Company to environmental, health, and safety laws, with non-compliance risking fines or operational interruptions.
• Gene Therapy Regulatory Changes: Regulatory requirements for gene therapy products are frequently changing, potentially lengthening the review process, increasing costs, or delaying commercialization.
• Data Privacy and Security: Subject to stringent and changing privacy and data security laws (e.g., CCPA, HIPAA); breaches or non-compliance could harm reputation, lead to fines, or disrupt clinical trials.

Geopolitical & External Risks

• International Operations Exposure: Operating internationally exposes the Company to various business, regulatory, political, operational, financial, and economic risks, including conflicting laws, tariffs, reduced intellectual property protection, and political instability.

Innovation & Technology Leadership

Research & Development Focus: Core Technology Areas:

• Gene Therapy: Focus on a proprietary, patented gene therapy platform to introduce the therapeutic "Klotho" protein for neurodegenerative diseases (Alzheimer's, ALS).
• Biosimilar Biologics: Development of off-patent bio generic antibodies for cancer treatment.
• Generic Drugs: Management of a portfolio of market-approved anti-cancer drugs.
• Assay Development: Development and validation of new in vitro assays to separate and individually measure the three Klotho protein isoforms (s-KL, m-KL, p-KL) and two metabolites (KL1, KL2) to support gene therapy development.
• Next-generation Delivery: Building a platform of AAV-based, Lentivirus-based, and lipid-based gene and cell delivery technologies to optimize investigational gene therapy products.

Innovation Pipeline:

• KLTO-101 (AAV9-CMV-sKL): Pre-clinical stage gene therapy product candidate for the treatment or prevention of Alzheimer's disease. The Company plans to seek a corporate partner for its development.
• KLTO-202 (AAVmyo-Des-sKL): Pre-clinical stage gene therapy product candidate for the treatment and prevention of Amyotrophic Lateral Sclerosis (ALS). The Company plans to complete the animal toxicology package and submit an Investigational New Drug (IND) application to the FDA in 2025 for a first-in-human Phase I "Compassionate Use" study in late-stage ALS patients.
• Recombinant s-KL protein: Potential to bring the recombinant s-KL protein into clinical trials to evaluate its safety and efficacy via infusion.

Intellectual Property Portfolio:

• Patent Strategy: The Company relies on a combination of licensed patents, trade secret protection, and confidentiality agreements. It plans to pursue new patent applications for its products.
• Patent Holdings:
  • α-Klotho gene (s-KL for neurodegenerative diseases): Issued patents in the U.S. (US Patent No. 12,036,268), Europe (EP3377091B1), China (CN108289933B), and Hong Kong (HK1259628A1), enforceable until November 21, 2036. Pending applications in Canada, China (DIV), Hong Kong (based on China DIV), Japan, US (CON), and US (DIV).
  • Neuromuscular Diseases (KLTO-202): Pending patent application (PCT/EP2023/059677) filed in major markets, with potential enforceability until April 16, 2043, if granted.
  • Modified AAV capsid polypeptides (for neuromuscular disorders): Pending patent applications (PCT/EP2019/060790 nationalized, pending in CA, US, EP, AU, JP, CN), with potential enforceability until April 26, 2039, if granted.
• Licensing Programs:
  • Exclusive, worldwide, royalty-bearing licenses with Universitat Autònoma de Barcelona (UAB) and Institució Catalana De Recerca I Estudis Avançades (ICREA) for s-KL diagnostics and therapeutics.
  • Exclusive, worldwide, royalty-bearing license with UAB, ICREA, Consorcio Centro de Investigación Biomédica en Red (CIBER), and Fundació Hospital Universitari Vall D’hebron — Institut de Recerca (VHIR) for Neuronal or Neuromuscular Diseases.
  • Non-exclusive, worldwide license with University of Heidelberg for modified AAV capsid polypeptides.
  • Exclusive, royalty-bearing license with Reliance Life Sciences (RLS) for biosimilars (rituximab, trastuzumab, bevacizumab, cetuximab).

Technology Partnerships:

• Universitat Autònoma de Barcelona (UAB): Strategic alliances through exclusive licensing agreements and a Sponsored Research Agreement for Klotho gene therapy.
• University of Heidelberg: Strategic alliance through a non-exclusive license for AAV capsid polypeptides.
• Reliance Life Sciences (RLS): Strategic alliance through an exclusive license and manufacturing/supply agreement for biosimilars.

Leadership & Governance

Executive Leadership Team

Leadership Continuity: Dr. Joseph Sinkule and Jeffrey LeBlanc are under three-year employment agreements. The Board of Directors has a single class of directors, with terms ending at the next annual stockholder meeting.

Board Composition: The Board of Directors consists of five members: Dr. Joseph Sinkule (CEO), Dr. Shalom Z. Hirschman, Dr. Samuel Zentman, Jon W. McGarity, and Riad El-Dada.

• Audit Committee: Composed of Samuel Zentman (Chairperson), Jon McGarity, and Riad El-Dada. All members meet Nasdaq and SEC independence and financial literacy requirements, with Samuel Zentman qualifying as an "audit committee financial expert."
• Compensation Committee: Composed of Jon McGarity (Chairperson), Samuel Zentman, and Shalom Hirschman. All members meet Nasdaq and SEC independence requirements.
• Nominating and Corporate Governance Committee: Composed of Shalom Hirschman (Chairperson), Jon McGarity, and Samuel Zentman. All members meet Nasdaq and SEC independence requirements. The Board members bring diverse expertise in business management, public and private company finance, medical technologies, drug development, and healthcare.

Human Capital Strategy

Workforce Composition:

• Total Employees: As of March 30, 2026, the Company has two full-time employees.
• Geographic Distribution: Following the March 2026 acquisition of Greenland Mines Corp., the Company gained three additional employees based in Europe.
• Skill Mix: Not explicitly detailed, but the Company's focus on drug development implies a need for scientific, technical, and management competencies.

Talent Management: Acquisition & Retention: The Company is highly dependent on its key executives and scientific/technical staff, particularly its CEO, Dr. Joseph Sinkule. It acknowledges intense competition for qualified personnel. Equity awards, including stock options and restricted stock, are utilized to link executive compensation to long-term performance, foster an ownership culture, and promote executive retention through time-based vesting features.

Diversity & Development: Specific diversity metrics or formal development programs were not explicitly detailed in the filing.

Environmental & Social Impact

Environmental Commitments: The Company's research, development, and manufacturing activities, as well as those of its third-party suppliers, involve the controlled storage, use, and disposal of hazardous materials. The Company and its suppliers are subject to laws and regulations governing these materials. While the Company believes its safety procedures comply with standards, it does not currently carry biological or hazardous waste insurance coverage.

Supply Chain Sustainability: Not explicitly detailed beyond general compliance with environmental laws.

Social Impact Initiatives: The Company's licensing agreements with Universitat Autònoma de Barcelona include a clause allowing termination if the Company illegally uses licensed rights, including violations of the Universal Declaration of Human Rights. The core business of developing essential medicines for chronic diseases inherently aims for social benefit.

Business Cyclicality & Seasonality

Demand Patterns: The Company's business is subject to demand volatility, which is identified as a market and financial risk. No specific seasonal trends or detailed economic sensitivity for its product candidates or industry cycles were explicitly disclosed.

Planning & Forecasting: Not explicitly detailed in the filing.

Regulatory Environment & Compliance

Regulatory Framework: Industry-Specific Regulations:

• U.S. FDA: The Company's pharmaceutical and biological product candidates are subject to extensive regulation by the FDA under the Federal Food, Drug, and Cosmetic Act (FDCA) and the Public Health Service Act (PHSA). This includes rigorous preclinical testing, Investigational New Drug (IND) application submission, human clinical trials (Phase 1, 2, 3), New Drug Application (NDA) or Biologics License Application (BLA) approval, and compliance with current Good Manufacturing Practices (cGMP) requirements. Post-approval, products are subject to ongoing requirements for manufacturing, labeling, reporting, and inspections.
• European Medicines Agency (EMA) and Other Foreign Authorities: Comparable regulatory authorities in Europe, Japan, and other countries impose their own requirements for product approval, which can be lengthy and vary by jurisdiction. The EU has an established biosimilar approval pathway since 2003.
• Gene Therapy Regulation: Gene therapy products are subject to frequently changing and evolving regulatory requirements, with the FDA's Office of Tissues and Advanced Therapies and the Cellular, Tissue and Gene Therapies Advisory Committee providing oversight. The FDA, NIH, and EMA have expressed interest in further regulating biotechnology, including gene therapy.
• Biosimilar Approval Pathway: The Biologics Price Competition and Innovation Act of 2009 (BPCIA) established an abbreviated pathway for biosimilar approval, requiring demonstration of biochemical and biologic biosimilarity to FDA-licensed "Reference Products."
• Healthcare Laws: The Company's business activities, including research, sales, promotion, and distribution, will be subject to federal and state healthcare fraud and abuse laws, such as the Anti-Kickback Statute, False Claims Act, Physician Payments Sunshine Act, and the Health Insurance Portability and Accountability Act (HIPAA), as amended by HITECH.

Trade & Export Controls: The export and import of biologic products are subject to extensive regulation. Specific details on trade restrictions, licensing requirements, or sanctions compliance were not provided beyond this general statement.

Legal Proceedings: The Company is subject to various legal proceedings and claims in the ordinary course of business, but management does not believe any will have a material effect on the Company's business, financial condition, results of operations, or cash flows. No material litigation or regulatory investigations were disclosed.

Tax Strategy & Considerations

Tax Profile:

• Effective Tax Rate: The statutory tax rate is 21%.
• Net Operating Losses: As of December 31, 2025, the Company had federal and state net operating loss (NOL) carryforwards of approximately $4,313,000 and $2,390,000, respectively, which do not expire. A full valuation allowance has been provided against these deferred tax assets due to the Company's lack of a history of generating taxable income.
• Geographic Tax Planning: Not explicitly detailed.
• Tax Reform Impact: The 2017 Act reduced the corporate tax rate to 21% and introduced limitations on NOL utilization (80% of taxable income for losses after 2017), with indefinite carryforward but generally no carryback.

Insurance & Risk Transfer

Risk Management Framework:

• Insurance Coverage: The Company carries Directors and Officers insurance, with prepaid expenses including the premium for this coverage.
• Risk Transfer Mechanisms: The Company does not currently carry biological or hazardous waste insurance coverage, which is identified as a risk given its R&D and manufacturing activities involving hazardous materials. No other specific risk transfer mechanisms were detailed.